Clinical trials: Chordomas
Chordoma
Sacral Chordoma: Surgery Versus Definitive Radiation Therapy in Primary Localized Disease
Comparative study on surgery versus definitive radiation therapy in primary localized sacral chordoma
- Trial name
- SACRO (NCT02986516)
- Testing
- Randomized Cohort, Prospective cohort
- Where
- 28 sites in Austria, Germany and 8 more
- Volunteers
- 100 people
- Sponsor
- Italian Sarcoma Group
Chordoma
Nilotinib With Radiation for High Risk Chordoma
The study drug, Nilotinib, is believed to slow down tumor growth by regulating a gene involved in cellular growth of chordoma cells.
- Trial name
- NCT01407198
- Testing
- Nilotinib, Radiation therapy
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Massachusetts General Hospital
Genes, Sporadic Chordoma
Genetic Clues to Chordoma Etiology: A Protocol to Identify Sporadic Chordoma Patients for Studies of Cancer-Susceptibility Genes
Background: Chordoma is a rare, slow growing, often fatal bone cancer derived from remnants of the embryonic notochord. It occurs mostly in the axial skeleton (skull base, vertebrae, sacrum and coccyx), is more frequent in males…
- Trial name
- NCT01200680
- Where
- United States
- Volunteers
- 188 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Head and Neck Cancer
A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6
This study evaluated the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study was conducted in patients with several types of refractory cancers including those at the surface of the…
- Conditions
- Breast Cancer, Head and Neck Cancer, Squamous Cell Carcinoma, Lymphoma
- Trial name
- IT-01 (NCT03058289)
- Testing
- INT230-6, anti-PD-1 antibody, anti-CTLA-4 antibody
- Where
- 8 sites in United States, Canada
- Volunteers
- 111 people
- Sponsor
- Intensity Therapeutics, Inc.
Chordoma, Chondrosarcoma
Hypofractionated Protontherapy in Chordomas and Chondrosarcomas of the Skull Base
The project is planned as a phase II clinical trial with a low level of intervention, for the prospective evaluation of the clinical results of radical or adjuvant treatment by proton therapy in chordomas and chondrosarcomas of…
- Trial name
- NCT05861245
- Testing
- 5-fraction hipofractionated protontheray, 25-fraction hypofractionated proton therapy
- Where
- Spain
- Volunteers
- 20 people
- Sponsor
- Quironsalud
Chordoma of Spine, Chordoma of Sacrum
High Dose Intensity Modulated Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine, Sacrum and Base of Skull
There are two types of external radiation treatments; proton beam and photon beam radiation. What type of therapy participants will receive will depend upon the location of their tumor.
- Conditions
- Chordoma of Spine, Chordoma of Sacrum, Chordoma of Base of Skull, Chondrosarcoma of the Spine
- Trial name
- NCT01346124
- Testing
- High Dose Intensity Modulated Proton Radiation
- Where
- 2 sites in United States
- Volunteers
- 64 people
- Sponsor
- Massachusetts General Hospital
Chordoma
QUILT-3.011 Phase 2 Yeast-Brachyury Vaccine Chordoma
This is a phase 2 clinical trial to determine whether the yeast-brachyury vaccine GI-6301 improves the effectiveness of radiation for patients with localized chordoma.
- Trial name
- NCT02383498
- Testing
- GI-6301 Vaccine (Yeast- Brachyury), Radiotherapy, wGT3X-BT Actigraph
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- NantCell, Inc.
Ewing Sarcoma, PEComa
Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers
This study investigates the safety/toxicity and potential anti-tumor activity of sequential administration of nivolumab and escalating doses of the mammalian target of rapamycin (mTOR) inhibitor nab-rapamycin (ABI-009) in…
- Conditions
- Ewing Sarcoma, PEComa, Epithelioid Sarcoma, Desmoid Tumor
- Trial name
- NCT03190174
- Testing
- Nab-Rapamycin, Nivolumab
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Sarcoma Oncology Research Center, LLC
Chordoma, HER2-positive Breast Cancer
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
A Phase 1 open label trial of intravenous administration of TAEK-VAC-HerBy vaccine in patients with advanced brachyury and/or HER2- expressing cancer. The study will be completed in 2 stages.
- Trial name
- NCT04246671
- Testing
- TAEK-VAC-HerBy
- Where
- 9 sites in United States
- Volunteers
- 37 people
- Sponsor
- Bavarian Nordic
Chordoma, Chemotherapy Effect
Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma
This phase II trial studies how well Camrelizumab combined with Apatinib work in treating participants with chordoma that has spread to other places in the body, which may interfere with the ability of tumor cells to grow and…
- Trial name
- NCT06140732
- Testing
- camrelizumab and apatinib
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Xuanwu Hospital, Beijing
Chordoma
A Study of ERAS-601 in People With Chordoma
The researchers are doing this study is to find out whether ERAS-601 is a safe and effective treatment that causes few or mild side effects in people with advanced and progressing chordoma.
- Trial name
- NCT06957327
- Testing
- ERAS-601
- Where
- 7 sites in United States
- Volunteers
- 12 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Chordoma
Children and Adults With Chordoma
Background: Chordoma is a rare type of bone cancer. It occurs in the skull base or spine. Researchers want to study people with chordoma in different ways.
- Trial name
- NCT03910465
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- National Cancer Institute (NCI)
Brain Tumor, Recurrent
Photodynamic Therapy (PDT) For Recurrent High Grade Gliomas
This study will be aimed at investigating the effectiveness of a treatment for brain tumors called Photodynamic Therapy, or PDT.
- Trial name
- NCT01966809
- Testing
- Photofrin photodynamic therapy.
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Harry T Whelan, MD
Chordomas, Chordoma
Pembrolizumab and Pemetrexed for Progressive Chordoma
Primary Objective: 1. To determine objective response rate (ORR) according to RECIST v1.1 of pembrolizumab and high-dose pemetrexed in the treatment of patients with chordoma until disease progression.
- Trial name
- NCT06794645
- Testing
- Pembrolizumab, Pemetrexed Phase 2
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Saint John's Cancer Institute
Chordoma
Genetic Aspects of Chordoma: A Collaboration With SEER Registries to Identify Chordoma Families
Chordoma is an uncommon (400 case/year in the U.S.) and potentially fatal bone tumor derived from remnants of embryonic notochord.
- Trial name
- NCT00341627
- Where
- 2 sites in United States
- Volunteers
- 56 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumors, Triple Negative Breast Cancer
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
The purpose of this "first-in-human" study of FAZ053 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of FAZ053 administered Intravenously (i.v.)as a single agent or…
- Conditions
- Advanced Solid Tumors, Triple Negative Breast Cancer, Chordoma and Alveolar Soft Part Sarcoma
- Trial name
- NCT02936102
- Testing
- FAZ053, PDR001
- Where
- 12 sites in United States, Canada and 7 more
- Volunteers
- 154 people
- Sponsor
- Novartis Pharmaceuticals
Rhabdomyosarcoma, Osteosarcoma
HSV1716 in Patients With Non-Central Nervous System (Non-CNS) Solid Tumors
Patients with relapsed solid tumors such as sarcomas and neuroblastoma have a poor survival, generally < 20%. There is an urgent need for new treatments that are safe and effective.
- Conditions
- Rhabdomyosarcoma, Osteosarcoma, Ewing Sarcoma, Soft Tissue Sarcoma
- Trial name
- NCT00931931
- Testing
- HSV1716
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Timothy Cripe
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Melanoma, Li-Fraumeni Syndrome
Clinical Genetics Branch Eligibility Screening Survey
Background: Clinical Genetics Branch (CGB) researchers study individuals and populations at high genetic risk of cancer in order to improve our understanding of cancer and to improve cancer care.
- Conditions
- Melanoma, Li-Fraumeni Syndrome, Pulmonary Blastoma, Chordoma
- Trial name
- NCT07005297
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- National Cancer Institute (NCI)
Chordoma, Metastatic Chordoma
Cetuximab for the Treatment of Advanced Unresectable or Metastatic Chordoma
This is a multicenter, single arm, phase 2 study designed to evaluate the efficacy and safety of cetuximab for the treatment of advanced (unresectable)/metastatic, chordoma.
- Conditions
- Chordoma, Metastatic Chordoma, Unresectable Chordoma
- Trial name
- NCT05041127
- Testing
- Cetuximab, Questionnaire Administration
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- M.D. Anderson Cancer Center